Dana Farber | Strategic Alliance Partners

Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.

Latest from Dana Farber

Choueiri and Motzer Chat on CheckMate-9ER and Other RCC Research

April 05, 2021

Podcast

In our exclusive interview, Dr. Choueiri and Dr. Motzer discuss the clinical implications of the phase 3 CheckMate-9ER trial in advanced renal cell carcinoma and how to best use the combination in practice.

On the Move: Narjust Duma Named Associate Director of the Cancer Equity Program at Dana-Farber

March 30, 2021

Article

Narjust Duma, MD, has been named as the new associate director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School.

Dr. Munshi on the FDA Approval of Idecabtagene Vicleucel in Multiple Myeloma

March 29, 2021

Video

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Dostarlimab Triplet Shows Antitumor Activity, Tolerability in Ovarian Cancer

March 20, 2021

Article

Dostarlimab plus niraparib and bevacizumab showcased favorable antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

Dr. Richardson on the Toxicity Profile of Melphalan Flufenamide in Multiple Myeloma

March 11, 2021

Video

Paul G. Richardson, MD, discusses the toxicity profile of melphalan flufenamide in relapsed/refractory multiple myeloma.

Belumosudil: Poised to Become Necessity in Chronic GVHD

March 09, 2021

Article

Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.